Amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig’s disease, is a relentless neurodegenerative disorder that attacks the motor neurons controlling voluntary muscle movement. Roughly 30,000 Americans live with the disease at any given time, and about 5,000 to 6,000 new cases are diagnosed each year per the CDC National ALS Registry. Despite its grim reputation, the field has changed in the past decade — three new disease-modifying therapies have been approved, and a growing roster of clinical trials offers options that did not exist for previous generations of patients.
How ALS Damages the Body
ALS destroys both upper motor neurons in the brain and lower motor neurons in the spinal cord. As these cells die, the muscles they control progressively weaken, twitch, and atrophy. Critically, ALS does not typically damage sensation, bowel and bladder function, or the muscles of the eyes — meaning patients remain fully aware as their bodies fail them.
Roughly 90 percent of cases are sporadic, with no clear family history. The remaining 10 percent are familial, often linked to mutations in C9orf72, SOD1, FUS, or TARDBP genes according to the NINDS. Average age at onset is 55 to 75, though young-onset cases occur.
Early Symptoms Are Often Subtle
Initial complaints depend on where motor neuron loss begins. About two-thirds of patients present with limb-onset symptoms — a foot that drops, a hand that drops things, calf cramps that do not resolve, or one arm that tires faster than the other. Bulbar-onset ALS, which begins in the muscles of the face and throat, accounts for the remaining third and shows up as slurred speech, choking on liquids, or unprovoked tongue twitching.
Fasciculations — visible muscle twitches under the skin — are a hallmark, but they alone do not indicate ALS. Most people with twitching muscles have benign fasciculation syndrome. The combination of weakness, atrophy, hyperreflexia, and progressive spread is what raises concern.
Diagnosis Takes Time
The average time from first symptom to confirmed diagnosis is 10 to 16 months, partly because no single test confirms ALS. Workup includes electromyography (EMG) showing widespread motor neuron damage, nerve conduction studies, MRI to rule out spinal cord compression or stroke, and bloodwork to exclude mimics like myasthenia gravis, multifocal motor neuropathy, and lead toxicity.
Newer diagnostic frameworks — the Gold Coast criteria published in 2020 — simplified the older El Escorial system and shortened the diagnostic delay in many centers. Mayo Clinic notes that experienced ALS centers reduce diagnostic delay and connect patients to multidisciplinary care faster.
Disease Progression
Median survival from symptom onset is 3 to 5 years, though about 10 percent of patients live 10 years or more. Stephen Hawking, who lived more than 50 years with the disease, was a famous outlier. Faster progression correlates with bulbar onset, older age, and rapid early decline; slower progression correlates with limb onset, younger age, and certain genetic variants.
The functional rating scale (ALSFRS-R) tracks decline across 12 domains scored 0 to 4. A typical patient loses about one point per month, though this varies widely. As respiratory muscles weaken, vital capacity falls and patients eventually require non-invasive ventilation.
When to seek emergency care: Call 911 or go to the nearest emergency room if a person with ALS develops sudden severe shortness of breath, choking that does not resolve, blue lips or fingernails, confusion or unusual sleepiness (signs of CO2 retention), or chest pain. Respiratory failure is the leading cause of death in ALS and can develop more rapidly than expected during infections.
Current Treatments
Three FDA-approved disease-modifying drugs are available. Riluzole, approved in 1995, extends survival by an average of 2 to 3 months. Edaravone, available as an IV infusion or oral suspension, modestly slows functional decline in selected patients. Tofersen, approved in 2023, targets SOD1-mediated ALS — about 2 percent of cases — and has shown promising biomarker effects.
Beyond pharmacotherapy, multidisciplinary ALS clinics improve survival by an estimated 6 to 12 months according to multiple cohort studies summarized in PMC. These clinics combine neurology, pulmonology, nutrition, speech therapy, physical therapy, social work, and palliative care under one roof, usually monthly.
Symptom management makes a major quality-of-life difference. Spasticity responds to baclofen and tizanidine. Cramps may improve with mexiletine. Pseudobulbar affect — uncontrolled laughing or crying — is treated with dextromethorphan-quinidine. Sialorrhea responds to anticholinergic patches or salivary gland botulinum toxin injections.
Respiratory and Nutritional Support
Non-invasive ventilation (BiPAP) extends life and dramatically improves comfort once forced vital capacity drops below 50 percent of predicted, sometimes earlier. Many patients use it overnight first, then expand to daytime as needed. Tracheostomy with invasive ventilation extends life further but is chosen by a minority of US patients.
Feeding tube placement (PEG) is recommended before significant respiratory decline because the procedure is safer at higher vital capacities. Nutrition affects survival; weight loss is an independent predictor of faster decline.
Living With ALS
Cognitive changes affect roughly 50 percent of patients, with about 15 percent meeting criteria for frontotemporal dementia. This overlap reflects shared genetics — particularly the C9orf72 expansion that causes both diseases. Family members and the care team should be alert to executive dysfunction and behavioral changes that complicate decision-making.
Adaptive equipment evolves as the disease progresses, from simple ankle-foot orthoses to power wheelchairs with eye-gaze controlled communication devices. The ALS Association loan closets distribute donated equipment at no charge in most regions. Our broader guide to chronic conditions touches on caregiving costs that often exceed insurance coverage.
Clinical Trials and What’s Coming
The therapeutic pipeline is the largest in ALS history. Antisense oligonucleotides targeting C9orf72 and FUS, stem cell therapies, and small molecules aimed at neuroinflammation are all in active trials. The HEALEY ALS Platform Trial at Mass General tests multiple drugs simultaneously against shared placebo, accelerating evaluation.
Patients can find trials through ClinicalTrials.gov and the ALS Association’s research portal. Genetic testing is increasingly recommended at diagnosis because some trials enroll only specific mutation carriers.
When to See a Doctor
Progressive painless weakness, especially asymmetric weakness in a single limb, deserves prompt neurology evaluation. So does new dysarthria, dysphagia, or unexplained weight loss. Fasciculations alone do not warrant alarm, but combined with weakness or atrophy they merit workup.
Many doctors recommend referral to an ALS Association Certified Treatment Center of Excellence once the diagnosis is suspected, even before it is confirmed, because earlier multidisciplinary involvement consistently correlates with better outcomes.
Frequently Asked Questions
Is ALS painful?
ALS itself does not directly cause pain because sensory nerves are spared, but secondary pain from muscle cramps, joint stiffness, and pressure points is common — affecting roughly 60 percent of patients. Most pain responds to standard medications, physical therapy, and proper positioning.
Can ALS be inherited?
About 10 percent of cases are familial, with the most common mutation being a hexanucleotide repeat expansion in C9orf72. Genetic counseling is offered to first-degree relatives of familial cases. The remaining 90 percent are sporadic with no clear inheritance pattern.
What causes ALS?
The cause remains incompletely understood. Current theories implicate protein misfolding, glutamate excitotoxicity, mitochondrial dysfunction, and neuroinflammation. Military service, certain occupational exposures, and high cardiovascular fitness have all been associated with elevated risk in epidemiological studies, though causation remains debated.
How is ALS different from MS?
Multiple sclerosis attacks the myelin sheath around nerves and is autoimmune; ALS destroys motor neurons themselves. MS typically presents with relapses and remissions; ALS progresses steadily. Sensation is affected in MS but generally preserved in ALS. Our multiple sclerosis guide details those differences.
The Bottom Line
ALS remains incurable, but the trajectory is no longer one of helpless waiting. Multidisciplinary clinics extend survival, three approved disease-modifying drugs are now available, and dozens of investigational therapies are in trials. Connecting early with an ALS Association Certified Center, considering genetic testing, and engaging palliative care alongside active treatment all improve quality of life. Patients and families who navigate this disease most successfully tend to make decisions about ventilation, feeding, and goals of care while still able to communicate clearly — long before crisis forces those choices.